Transaction Overview - BD will separate its Biosciences and Diagnostic Solutions business to BD shareholders and simultaneously merge SpinCo with a wholly owned subsidiary of Waters in a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion[65] - Expected pro forma ownership of 60.8% for Waters shareholders and 39.2% for BD shareholders[65] - BD to receive approximately $4 billion cash distribution via proceeds of SpinCo debt[65] - The transaction is expected to close around the end of the first quarter of calendar year 2026[65] Financial Highlights - Pro forma revenue for CY 2025E is approximately $6.5 billion[18] - Adjusted EBITDA for CY 2025E is approximately $2.0 billion[18] - R&D spending is approximately 10% of sales[18] - The transaction is expected to be EPS accretive in Year 1[36] - Expected revenue synergies of approximately $290 million by Year 5, with an EBITDA impact of $145 million[33, 61] - Expected cost synergies of approximately $200 million by Year 3[33, 61] - Approximately $345 million in total annualized adjusted EBITDA synergies are expected by Year 5[36, 61] Growth and Stability - The combined company will have a total addressable market (TAM) of approximately $40 billion with 5-7% market growth[19, 22] - Over 70% of revenue is annually recurring[19, 30] - Over 50% of instruments are replaced every 5-10 years[19, 30] - Expected sales growth in the near-to-mid-term is MSD-HSD (Mid-Single-Digit to High-Single-Digit)[33] - Adjusted operating margin expansion of approximately 500 bps is expected by 2030[33]

导读： 本 次采购申请总金额约15.3亿元，主要用于仪器设备，占比超99%（约15.2亿元），少量涉及图 书和电动机。以下是各校采购申请的汇总信息。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 第四届微课大赛参赛作品抢先看！ 报名咨询：魏老师 15011302316（微信同号） 赞助咨询：李先生 18513107388（微信同号） 在当今数字化教育浪潮中，微课以其短小精悍、主题明确、针对性强等特点，逐渐成为教育领 域中一种备受瞩目的教学资源形式。为了进一步推动教育创新，促进教师之间的经验交流与共 享， 中国分析测试协会高校分析测试分会已经联合 成功举办了 3 届微课大赛。大赛吸引了众 多教育工作者的积极参与，收到了来自全国各地的大量优秀作品。 第四届微课大赛已于 4月份正式启动！目前已收到来自23个院校的报名信息！ 登录官网立即报名 第四届微课大赛参赛日程及奖励！ ↓ 更多微课作品 ↓ 大赛赞助单位： 发 文 不 易 ， 请 帮 小 编 点 下 "❤️" | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 ...

导读： 华谱科仪完成过亿元Pre-B轮融资，致力于推进国产液相色谱技术革新与应用，打破进口垄断局面。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，国产色谱设备、软件和耗材全体系平台企业 华谱科仪（北京）科技有限公司（以下简称"华谱科仪"） 已完成过 亿元 Pr e -B轮融资，本轮融资由京国瑞基金和北工投资在管的北京高精尖基金共同领投，老股东弘晖基金、架桥资本 跟投 ，本轮所融资金将主要用于国内外销售渠道的进一步建设和下一代产品的开发。 长海资本持续担任公司融资的独 家财务顾问 。 自2 0 1 5年成立以来，华谱科仪已建立起HPLC（高效液相色谱仪）、UHPLC（超高效液相色谱仪）以及配套的软件和 对应耗材的一系列产品矩阵。目前公司自有品牌仪器在色谱主流应用市场保有量达到数千台。华谱科仪凭借成熟完备的 合规化软件系统与服务体系，在国产液相色谱领域构建起显著的竞争优势，是行业内为数不多可以成体量进入海关、质 检、药监等制标单位，以及药企、CRO企业等关键商业化客户的厂商。 在现有产品以外，华谱科仪还在不断地拓展产品矩阵，从 ...

Maravai LifeSciences (MRVI) Q1 2025 Earnings Call May 12, 2025 05:00 PM ET Company Participants Deb Hart - Head of Investor RelationsTrey Martin - CEOKevin Herde - Executive VP & CFODan Arias - Managing DirectorBecky Buzzeo - Executive VP & Chief Commercial OfficerBrandon Couillard - Managing Director Conference Call Participants Conor McNamara - Equity Research AnalystDan Leonard - Managing Director & Research AnalystTejas Savant - Executive Director & Senior Healthcare Equity AnalystMatthew Stanton - Anal ...

Financial Data and Key Metrics Changes - The company reported $47 million in revenue for Q1 2025, exceeding expectations and showing a growth of over $4 million from Q4 2024 [6][27] - GAAP net loss before noncontrolling interests was $53 million for Q1 2025, compared to a loss of $23 million in Q1 2024 [27] - Adjusted EBITDA was negative $11 million for Q1 2025, down from a positive $8 million in Q1 2024 [28] - Basic and diluted EPS for Q1 was a loss of $0.21 per share, compared to a loss of $0.09 per share in Q1 2024 [30] Business Line Data and Key Metrics Changes - The Nucleic Acid Production (NAP) segment generated $29 million in revenue for Q1 2025, an increase of $1 million from Q4 2024 [6] - The Biologics Safety Testing (BST) segment reported $18 million in revenue for Q1 2025, up $3 million from Q4 2024 and flat compared to Q1 2024 [6][35] - The adjusted EBITDA margin for the BST segment was 70%, indicating strong performance [35] Market Data and Key Metrics Changes - Revenue by customer type in Q1 was 29% from biopharma, 28% from life science and diagnostics, 6% from academia, 7% from CDMO, and 30% through distributors [7] - Revenue by geography was 62% from North America, 15% from EMEA, 15% from Asia Pacific, and 8% from China [7] Company Strategy and Development Direction - The company is focused on a return to growth strategy and building a diversified franchise as a life science tool provider and clinical partner [10] - The strategy includes vertical integration in the NAP segment to enhance quality, speed, and cost efficiency [8] - The company aims to expand its product and service portfolio to drive long-term sustainable growth [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges of transitioning from a COVID-driven revenue model to a more diversified business [39] - The company is closely monitoring trade dynamics and working to mitigate potential impacts from tariffs [39] - The cash position of $285 million is seen as sufficient to manage the reset period while focusing on long-term growth [40] Other Important Information - The company plans to publish its 2024 sustainability report, highlighting its commitment to sustainability and long-term strategic objectives [25] - The integration of recent acquisitions is progressing well, enhancing operational capabilities and supply chain control [32] Q&A Session Summary Question: Focus areas for new trials and reasons for discontinuation - Management noted that while preclinical programs were flat, clinical programs showed growth, indicating a focus on later-stage projects due to funding conservatism [44][46] Question: Drivers of incremental demand in the next 12-18 months - Incremental demand is expected from clinical progression, new business wins, and the transition from bulk reagent supply to comprehensive service offerings [48] Question: Opportunities for market share due to U.S. manufacturing - The company sees potential for market share growth as interest in U.S.-based manufacturing increases, particularly in the mRNA space [51][54] Question: Impact of U.S. policy changes on customer buying patterns - Customers are experiencing mixed impacts from government funding changes, with some securing long-term funding while others delay decisions [60] Question: Government work and exposure - The company has no direct government work currently, with past contracts fulfilled, but remains open to future opportunities [66] Question: Seasonality in BST revenue - Q1 is typically a high point for BST revenue, influenced by manufacturing cycles and strong performance in China [70][72]

Waters (WAT) Q1 2025 Earnings Call May 06, 2025 08:00 AM ET Speaker0 Good morning. Call is being recorded. If you have any objections, please disconnect at this time. It is now my pleasure to turn the call over to mister Caspar Tudor, head of investor relations. Please go ahead, sir. Speaker1 Thank you, Leila, and good morning, everyone. Welcome to Walters Corporation's first quarter earnings call. Joining me today are doctor Udit Batra, our president and chief executive officer and Amol Chawwal, our senior ...

Waters (WAT) Q1 2025 Earnings Call May 06, 2025 08:00 AM ET Company Participants Caspar Tudor - Head, Investor RelationsUdit Batra - President and CEOAmol Chaubal - Senior VP & CFOTycho Peterson - Managing DirectorPuneet Souda - Senior MDBrandon Couillard - Managing DirectorVijay Kumar - Senior Managing DirectorDan Arias - Managing DirectorDaniel Brennan - Managing Director Conference Call Participants Jack Meehan - Equity Research AnalystCatherine Schulte - Senior Research AnalystSung Ji Nam - Managing Dir ...

Q1 2025 Earnings Call Presentation May 6, 2025 Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements regarding future results and events, including financial and operational guidance and projected estimates. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "outlook," and similar expressions (as well as ...

证券研究报告 | 公司动态点评 2025 年 04 月 30 日 创耀科技（688259.SH） 下游需求放缓，业绩短期承压。2024 年受全球经济增速放缓及终端市场整体 需求下降的影响，公司接入网业务规模有所下降。2024 年公司实现主营业务 收入 5.92 亿元，同比下降 10.44%。实现归母净利润 6047.48 万元，同比增 长 3.48%，实现扣非后归母净利润 4510.07 万元，同比增长 4.42%。其中 24Q4 单季度实现营收 1.64 亿元，同比下降 20.5%，环比增长 15.3%；单季 度归母净利润 1358.85 万元，同比下降 26.21%，环比增长 14.01%。分产品 看，2024 年公司软件与集成电路业务收入同比下降 10.44%，通信芯片与解 决方案业务营业收入同比下降 15.10%，营业成本同比下降 8.81%，毛利率 下降 4.89 pct；其中接入网网络芯片及解决方案业务中的产品以及技术开发 服务取得的营业收入同比小幅下降，电力线载波通信芯片与解决方案业务取 得的营业收入同比小幅增长。芯片版图设计服务营收同比增长 13.23%，毛 利率为 21.28%。从费用端看： ...

Core Viewpoint - The company, Chuangyao Technology, reported a steady growth in revenue and profit for 2024, achieving an operating income of 592 million yuan and a net profit of 45.1 million yuan, reflecting a year-on-year growth of 4.42% despite a complex market environment [1] Group 1: Financial Performance - In 2024, the company achieved an operating income of 592 million yuan and a net profit of 45.1 million yuan, marking a 4.42% increase year-on-year [1] - The company plans to focus on existing core businesses while enhancing market development and integration capabilities for higher quality growth in 2025 [1] Group 2: R&D and Innovation - The company increased its R&D investment to 124 million yuan, accounting for 21.02% of its operating income, to drive innovation and product development [2] - The company is expanding its application fields in core technologies such as power line carrier communication chips and access network chips, which are crucial for long-term growth [2] - The company is actively developing short-range wireless chips for various IoT devices, aiming to capture new business opportunities in the mid-to-high-end wireless terminal market [3] Group 3: Strategic Investments - The company is strategically investing in high-quality enterprises in the semiconductor design and communication equipment sectors to enhance its competitive edge and extend its industry chain [4] - A collaborative mechanism involving professional investment institutions, government-guided funds, and industrial capital has been established to identify high-growth potential startups [4] - The company plans to continue leveraging capital to implement strategic acquisitions of quality assets while enhancing the operational efficiency of invested enterprises [4] Group 4: Shareholder Returns - The company has implemented various shareholder return mechanisms, including cash dividends and share buybacks, to enhance investor rights protection [6] - A cash dividend of 4.5 yuan per 10 shares is proposed, totaling 4.99 million yuan, which represents 35.78% of the net profit attributable to the parent company for 2024 [6] - The cash dividend ratio has increased from 30.50% in 2021 to 35.78% in 2024, demonstrating a commitment to sharing development results with investors [6]